M24-311: A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (Enrollment Paused: October 8, 2025)

Objective

Clinical Trial Details

Principal Investigator(s)

Heidi McKean, MD

Clinical Trial Categories

• Cancer
• Colorectal Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org